[go: up one dir, main page]

AR074304A1 - Moduladores heterociclicos de gamma- secretasa - Google Patents

Moduladores heterociclicos de gamma- secretasa

Info

Publication number
AR074304A1
AR074304A1 ARP090104314A ARP090104314A AR074304A1 AR 074304 A1 AR074304 A1 AR 074304A1 AR P090104314 A ARP090104314 A AR P090104314A AR P090104314 A ARP090104314 A AR P090104314A AR 074304 A1 AR074304 A1 AR 074304A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
halogen
hydroxy
substituted
cyano
Prior art date
Application number
ARP090104314A
Other languages
English (en)
Inventor
Anja Limberg
Thomas Luebbers
Karlheinz Baumann
Synese Jolidon
Erwin Goetschi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR074304A1 publication Critical patent/AR074304A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere al uso de compuestos de la fórmula (1) en la que R1 es un grupo heteroarilo de cinco o seis eslabones, opcionalmente sustituido por uno o dos R'; R' es alquilo inferior, R2 es H, alquilo inferior, alcoxi inferior, hidroxi halógeno o ciano; Z es N, C, O o S; V es N, C(R"), O o S; W es N, C(R"), O o S, Y es N o C; con la condición de que solo uno de Z, V o W puede ser O o S; R" es H, alquilo inferior, alquilo inferior sustituido por halógeno o hidroxi, o es C(O)O-R4; L es un enlace, -(CR42)n-, -C(O)NR4-, -C(O)NR4CH2-, o -C(O)-; R4 puede ser el mismo o diferente y es hidrógeno o alquilo inferior; R3 es alquilo inferior, alcoxi inferior, alquilo inferior sustituido por hidroxi, fenilo opcionalmente sustituido por uno o más R"' o es cicloalquilo; R"' es halógeno, ciano, alquilo inferior, alquilo inferior sustituido por halógeno o hidroxi, o es alcoxi inferior o es C(O)O-R4; n es el número 1, 2 o 3; o las sales de adición de ácido farmacéuticamente activas para la fabricación de medicamentos destinados al tratamiento de la enfermedad de Alzheimer, la angiopatía amiloide cerebral, la hemorragia cerebral hereditaria con amiloidosis de tipo Dutch (HCHWA-D), la demencia multi-infarto, la demencia pugilística o el síndrome de Down. Reivindicación 5: Un compuesto de la fórmula (1-A) comprendido en la fórmula (1) de la reivindicación 1 en la que R1 es un grupo heteroarilo de cinco o seis eslabones, opcionalmente sustituido por uno o dos R', elegido entre el grupo de fórmulas (2); R' es alquilo inferior; R2 es hidrógeno, alquilo inferior, alcoxi inferior, hidroxi, halógeno o ciano; Z es N, C, O o S; V es N, C(R''), O o S; W es N, C(R''), O o S; Y es N o C; con la condición de que solo uno de Z, V o W puede ser O o S; R'' es hidrógeno, alquilo inferior, alquilo inferior sustituido por halógeno o hidroxi, o es C(O)O-R4; L es -(CR42)n-, -C(O)NR4-, -C(O)NR4CH2-; R4 puede ser el mismo o diferente y es hidrógeno o alquilo inferior; R3 es alquilo inferior, fenilo opcionalmente sustituido por uno o más R"' o es cicloalquilo; R"' es halógeno, ciano, alquilo inferior, alquilo inferior sustituido por halógeno o hidroxi, o es alcoxi inferior o es C(O)O-R4; n es el número 1, 2 o 3; o las sales de adición de ácido farmacéuticamente activas del mismo.
ARP090104314A 2008-11-10 2009-11-09 Moduladores heterociclicos de gamma- secretasa AR074304A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08168719 2008-11-10

Publications (1)

Publication Number Publication Date
AR074304A1 true AR074304A1 (es) 2011-01-05

Family

ID=41728178

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104314A AR074304A1 (es) 2008-11-10 2009-11-09 Moduladores heterociclicos de gamma- secretasa

Country Status (13)

Country Link
US (1) US8288403B2 (es)
EP (1) EP2355817A1 (es)
JP (1) JP5378532B2 (es)
KR (1) KR101293421B1 (es)
CN (1) CN102209537A (es)
AR (1) AR074304A1 (es)
AU (1) AU2009312856A1 (es)
BR (1) BRPI0921348A2 (es)
CA (1) CA2743196A1 (es)
IL (1) IL212497A0 (es)
MX (1) MX2011004954A (es)
TW (1) TW201021795A (es)
WO (1) WO2010052199A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2481715T3 (es) 2009-02-06 2014-07-31 Janssen Pharmaceuticals, Inc. Compuestos heterocíclicos bicíclicos sustituidos novedosos como moduladores de gamma-secretasa
AU2010262036B2 (en) 2009-05-07 2014-10-30 Cellzome Limited Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
BR112012000915A2 (pt) 2009-07-15 2019-09-24 Janssen Pharmaceuticals Inc derivados de triazol e imidazol substituídos como moduladores de gama secretase.
CA2784765A1 (en) * 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic triazole derivatives as gamma secretase modulators
CN103502225B (zh) 2011-03-24 2015-11-25 杨森制药公司 作为γ分泌酶调节剂的经取代的三唑基哌嗪以及三唑基哌啶衍生物
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
AU2012285931B2 (en) 2011-07-15 2017-01-12 Cellzome Limited Novel substituted indole derivatives as gamma secretase modulators
KR102096625B1 (ko) 2012-05-16 2020-04-03 얀센 파마슈티칼즈, 인코포레이티드 (무엇보다도) 알츠하이머병의 치료에 유용한 치환 3,4-디하이드로-2h-피리도[1,2-a]피라진-1,6-디온 유도체
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
KR102209418B1 (ko) 2012-12-20 2021-01-29 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 삼환 3,4-디하이드로-2H-피리도[1,2-α]피라진-1,6-디온 유도체
CA2891755C (en) 2013-01-17 2021-10-26 Janssen Pharmaceutica Nv Substituted pyrido-piperazinone derivatives as gamma secretase modulators
DK3004079T3 (en) 2013-06-04 2018-04-16 Acturum Real Estate Ab PYRIMIDE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS
JP6368776B2 (ja) 2013-06-04 2018-08-01 アクチュラム・ライフ・サイエンス・アクチエボラーグ トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
JP6396438B2 (ja) 2013-06-04 2018-09-26 アクチュラム・ライフ・サイエンス・アクチエボラーグ トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用
JP6532646B2 (ja) * 2013-12-06 2019-06-19 ロレアル パウダー状化粧用組成物
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
BR112017015693A2 (pt) 2015-02-03 2018-03-20 Pfizer ciclopropabenzofuranil piridopirazinadionas
KR101719419B1 (ko) * 2015-08-05 2017-03-23 건국대학교 산학협력단 베타 아밀로이드의 올리고화 및 섬유화 저해능과 함께 신경세포 보호능력을 갖는 신규 알츠하이머병 치료제
JP6831372B2 (ja) * 2015-09-09 2021-02-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 架橋ピペリジン誘導体
WO2018106646A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
DK3568489T3 (da) 2017-01-12 2021-11-15 Vib Vzw Screeningstest for gamma-sekretasestabiliserende forbindelser

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751742T3 (de) 1986-01-13 2002-11-21 American Cyanamid Co., Wayne 4,5,6-Substituierte 2-Pyrimidinamine
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
US5686070A (en) * 1994-03-03 1997-11-11 Genentech, Inc. Methods for treating bacterial pneumonia
CN1208412A (zh) 1995-12-14 1999-02-17 麦克公司 促性腺激素释放激素拮抗剂
DE69923681T2 (de) 1998-06-18 2006-01-12 Bristol-Myers Squibb Co. Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
JP2002528499A (ja) * 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
SE9803773D0 (sv) 1998-11-05 1998-11-05 Astra Pharma Prod Compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
WO2001005774A1 (en) 1999-07-15 2001-01-25 Sumitomo Pharmaceuticals Co., Ltd. Heteroaromatic ring compounds
IL150420A0 (en) 1999-12-28 2002-12-01 Pharmacopeia Inc Pyrimidine and triazine kinase inhibitors
US20030176454A1 (en) * 2000-05-15 2003-09-18 Akira Yamada N-coating heterocyclic compounds
EP1355889B1 (en) * 2000-12-22 2006-06-07 Ortho-McNeil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
IL159041A0 (en) 2001-06-28 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
MXPA04007590A (es) 2002-02-05 2004-12-06 Yamanouchi Pharma Co Ltd Derivado de 2,4,6-triamino-1,3,5-triacina.
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
WO2004005262A2 (en) * 2002-07-02 2004-01-15 Schering Corporation New neuropeptide y y5 receptor antagonists
AU2004209986C1 (en) 2003-02-03 2009-08-13 Gilead Palo Alto, Inc. Partial and full agonists of A1 adenosine receptors
AU2004225977B2 (en) 2003-03-25 2011-03-24 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
US7244739B2 (en) * 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
CN1787822A (zh) * 2003-05-14 2006-06-14 托里派因斯疗法公司 化合物及其在调节淀粉样蛋白β中的用途
WO2005003103A2 (en) 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
JP4741491B2 (ja) 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
US20080234305A1 (en) 2003-10-09 2008-09-25 Olivier Bezencon Novel Tetrahydropyridine Derivatives
CN1871208A (zh) 2003-10-30 2006-11-29 默克公司 作为大麻素受体调节剂的芳烷基胺
EP1699292A1 (en) * 2003-12-24 2006-09-13 Bayer CropScience GmbH Plant growth regulation
US7649002B2 (en) * 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
HRP20080227T3 (hr) 2004-10-15 2008-06-30 Glaxo Group Limited Pirolidinski derivati kao ligandi histaminskih receptora
BRPI0516915A (pt) 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
WO2007051333A1 (en) 2005-11-02 2007-05-10 Oncalis Ag Triazine beta-secretase inhibitors
WO2007054480A1 (en) 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
US20090048448A1 (en) 2005-11-18 2009-02-19 Ikuo Kushida Salts of cynnamide compound or solvates thereof
CN101309916A (zh) 2005-11-18 2008-11-19 卫材R&D管理有限公司 制备肉桂酰胺衍生物的方法
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
EP1953154A4 (en) * 2005-11-24 2013-11-20 Eisai R&D Man Co Ltd CINNAMIDE COMPOUNDS OF MORPHOLINE TYPE
AU2006342024A1 (en) 2005-12-16 2007-10-25 Genentech, Inc. Tetracyclic kinase inhibitors
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
KR101464651B1 (ko) 2006-03-09 2014-11-24 에자이 알앤드디 매니지먼트 가부시키가이샤 다환식 신나미드 유도체
DE502006004066D1 (de) 2006-04-19 2009-08-06 Boehringer Ingelheim Pharma Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
CN101448797A (zh) 2006-05-19 2009-06-03 卫材R&D管理有限公司 杂环类型肉桂酰胺衍生物
EP2019093A4 (en) * 2006-05-19 2011-02-23 Eisai R&D Man Co Ltd CINEMA ACID AMID DERIVATIVE FROM THE UREA TYPE
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
WO2008006103A2 (en) 2006-07-07 2008-01-10 Wyeth Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
WO2008065626A2 (en) 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors
WO2008097538A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
CA2676920A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperidine derivatives
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
RU2009140182A (ru) * 2007-05-11 2011-06-20 Ф. Хоффманн-Ля Рош Аг (Ch) Гетариланилины в качестве модуляторов для бета-амилоида
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
ES2535166T3 (es) 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
EP2200990A1 (en) 2007-09-06 2010-06-30 Schering Corporation Gamma secretase modulators
JP2011506460A (ja) 2007-12-11 2011-03-03 シェーリング コーポレイション γ−セクレターゼモジュレーター
EP2234999A1 (en) * 2007-12-21 2010-10-06 F. Hoffmann-La Roche AG Heteroaryl derivatives as orexin receptor antagonists
ATE535515T1 (de) * 2008-01-11 2011-12-15 Hoffmann La Roche Modulatoren für amyloid beta
EP2257541B1 (en) * 2008-02-22 2013-08-14 F. Hoffmann-La Roche AG Modulators for amyloid beta
CA2727036C (en) 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
CN102333777B (zh) 2009-02-26 2014-06-25 卫材R&D管理有限公司 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途

Also Published As

Publication number Publication date
MX2011004954A (es) 2011-05-30
KR20110083731A (ko) 2011-07-20
TW201021795A (en) 2010-06-16
CA2743196A1 (en) 2010-05-14
WO2010052199A1 (en) 2010-05-14
JP2012508211A (ja) 2012-04-05
US20100120874A1 (en) 2010-05-13
AU2009312856A1 (en) 2010-05-14
US8288403B2 (en) 2012-10-16
KR101293421B1 (ko) 2013-08-05
BRPI0921348A2 (pt) 2019-09-24
JP5378532B2 (ja) 2013-12-25
CN102209537A (zh) 2011-10-05
EP2355817A1 (en) 2011-08-17
IL212497A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
AR074304A1 (es) Moduladores heterociclicos de gamma- secretasa
ECSP13012858A (es) Derivados de piperidina puenteada
AR080083A1 (es) Moduladores de gamma-secretasa
AR109829A1 (es) Derivados de piperidina puenteados
AR070437A1 (es) Moduladores de beta - amiloide
AR080177A1 (es) Derivados de piperidina, un procedimiento para su preparacion, y su uso en medicamentos para el tratamiento de enfermedades mentales asociadas a la deposicion del beta-amiloide en el cerebro.
AR107010A1 (es) Derivados de piperidina puenteados
AR075139A1 (es) Compuestos biciclicos para la reduccion de la produccion de beta-amiloide
MX2018000592A (es) Derivados de etinilo como moduladores del receptor de glutamato metabotropico.
AR110122A1 (es) Fenoxitriazoles
AR110001A1 (es) Derivados heteroarilo bicíclicos
AR070130A1 (es) Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR076753A1 (es) Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides.
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR056560A1 (es) Pirrolopiridinonas como moduladores cb1
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR065280A1 (es) Agentes antiparasitarios
AR078321A1 (es) Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9)
AR077505A1 (es) Compuestos de piridina y sus usos
AR082015A1 (es) Derivados de metoxifenilo heterociclicamente sustituidos con un grupo oxo, procedimientos para su preparacion y uso de los mismos como medicamentos
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR083003A1 (es) Lactamas sustituidas por piperidinilo como moduladores de gpr119
AR105965A1 (es) Derivados de piperidina puenteados

Legal Events

Date Code Title Description
FB Suspension of granting procedure